Georgia Tomaras
Chief, Division of Surgical Sciences
A. Geller Distinguished Professor for Research in Immunology
Professor in Surgery
Professor in Integrative Immunobiology
Professor in Molecular Genetics and Microbiology
Affiliate, Duke Global Health Institute
Dr. Tomaras' overall research program is to understand the cellular and humoral immune response to HIV-1 infection and vaccination that are involved in protection from HIV-1. The research in the Tomaras laboratory centers around three main projects involving 1) antiviral CD8 T cell responses in HIV-1 infection and post vaccination, 2) mucosal and systemic antibody responses to infection and vaccination in both non-human primates and humans and 3) the ontogeny of neutralizing antibodies in HIV-1 infection. Her laboratory is also within the Duke Human Vaccine Institute.
Projects
-
Improved Global HIV-1 Incidence Assay
United States
Publications
-
Gray GE, Mngadi K, Lavreys L, Nijs S, Gilbert PB, Hural J, et al. Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Infect Dis. 2024 Nov;24(11):1201–12.Spreng RL, Seaton KE, Lin L, Hilliard S, Horn GQ, Abraha M, et al. Identification of RTS,S/AS01 vaccine-induced humoral biomarkers predictive of protection against controlled human malaria infection. JCI Insight. 2024 Oct 8;9(19).Hahn WO, Parks KR, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, et al. Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies. J Exp Med. 2024 Oct 7;221(10).Woolley G, Kroll K, Hoffman K, Ward A, Corneli A, Mudrak SV, et al. The Climate Change Burden on Immune Health: Are Persons Living with HIV More at Risk? AIDS Res Hum Retroviruses. 2024 Oct;40(10):549–54.
See more publications at Scholars@Duke